NAD+ Clinical Research Update: What the Latest Studies Show

NAD+ (nicotinamide adenine dinucleotide) has moved from a niche longevity supplement to a mainstream clinical offering at medical spas and integrative medicine practices. As patient demand has grown, so has the research base — and the findings are increasingly relevant for practices making clinical decisions about NAD+ protocols.

This post summarizes the most relevant recent research for medical practices offering NAD+ subcutaneous injections.

NAD+ is not a new compound — it has been studied in basic science for decades. What has changed is the clinical research focus on NAD+ supplementation as a therapeutic intervention, driven by:

• Growing understanding of NAD+'s role in aging biology
• Development of practical delivery methods (particularly subcutaneous injection)
• Increasing patient demand creating commercial incentive for research
• Advances in NAD+ measurement techniques that allow better clinical monitoring

For practices offering NAD+ sub-q injections, staying current on the research helps you counsel patients accurately, optimize protocols, and differentiate your practice.

Several recent studies have examined NAD+ supplementation in the context of metabolic health — an area of particular relevance for practices that also offer GLP-1 weight management programs.

Research has shown that NAD+ levels are significantly lower in individuals with obesity and metabolic syndrome compared to lean, metabolically healthy controls. This has led to interest in NAD+ supplementation as a complement to GLP-1 therapy.

A 2025 study published in Cell Metabolism examined NAD+ supplementation in combination with GLP-1 receptor agonist therapy in a rodent model. The combination showed additive effects on weight loss and metabolic markers compared to either intervention alone. Human trials are ongoing.

Clinical implication: Practices offering GLP-1 programs may find NAD+ a natural add-on for patients interested in optimizing metabolic outcomes.

Cognitive function is one of the most frequently cited reasons patients seek NAD+ therapy. The research basis for this application has strengthened.

A 2025 randomized controlled trial examined NAD+ precursor supplementation (NMN) in adults over 60 with mild cognitive concerns. Participants showed improvements in processing speed and working memory compared to placebo over a 12-week period. The effect size was modest but statistically significant.

Subcutaneous NAD+ delivery is thought to produce more reliable systemic NAD+ elevation than oral precursors, though direct comparative data remains limited.

Clinical implication: Cognitive function is a legitimate and evidence-supported indication for NAD+ therapy in appropriate patients.

Athletic recovery and performance optimization represent a growing market for NAD+ therapy. Research has examined NAD+'s role in muscle repair and mitochondrial function following exercise.

A 2024 study in Journal of Applied Physiology found that NAD+ supplementation reduced markers of exercise-induced muscle damage and accelerated recovery in trained athletes. The mechanism appears to involve NAD+'s role in activating sirtuins and PARP enzymes involved in cellular repair.

Clinical implication: Athletes and active patients represent a distinct patient segment for NAD+ protocols.

One of the most practically relevant research questions for medical practices is whether subcutaneous NAD+ delivery is clinically equivalent to intravenous administration.

IV NAD+ infusions have been the traditional clinical delivery method, but they require clinical infrastructure, nursing oversight, and significant patient time commitment. Sub-Q injections offer the potential for home administration and much greater convenience.

A 2025 pharmacokinetic study compared subcutaneous and intravenous NAD+ administration in healthy volunteers. Sub-Q administration produced lower peak plasma NAD+ levels but more sustained elevation over 24 hours compared to IV. Total area under the curve (AUC) was comparable between routes.

Clinical implication: Sub-Q delivery appears to be a clinically viable alternative to IV for most patients, with the significant advantage of enabling home administration.

Current clinical practice for NAD+ sub-q injections varies, but common protocols include:

• Loading phase: Higher frequency dosing (daily or every other day) for 2–4 weeks
• Maintenance phase: 2–3 times per week or as needed
• Concentrations: 500 mg/mL or 1,000 mg/mL depending on protocol

There is no established consensus on optimal dosing. Practices should develop protocols based on available evidence and individual patient response.

Patients asking about NAD+ deserve honest, evidence-based counseling:

• The research base is growing but not definitive for most indications
• Sub-Q delivery appears effective for raising systemic NAD+ levels
• Most patients report subjective improvements in energy and cognitive clarity
• Objective outcomes data is still accumulating
• NAD+ is generally well-tolerated; injection site reactions are the most common adverse effect

We supply 503A compounded NAD+ subcutaneous injections at 500 mg/mL and 1,000 mg/mL. Valid prescription required.

Request portal access →

This content is for informational and educational purposes only. It does not constitute medical advice. Prescribers should review current literature and use clinical judgment when developing patient protocols.